

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Otrivine Adult 0.1% w/v Nasal Drops, Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Xylometazoline Hydrochloride 0.1% w/v

Excipients: Benzalkonium chloride 0.01% w/v.

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Nasal drops, solution (nasal drops)

A clear, colourless solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

As a nasal decongestant for relief of the symptoms of acute rhinitis in allergic or upper respiratory tract infections, including the common cold or influenza. Relief of sinusitis.

4.2 Posology and method of administration

Adults (including the elderly) and adolescents over 12 years of age:

Otrivine should not be used for more than seven consecutive days (see section 4.4).
The recommended dose should not be exceeded, especially in children and the elderly.

Adults (including the elderly) and adolescents over 12 years of age: 2 to 4 drops into each nostril, up to 3 times daily as needed. Do not exceed 3 applications daily into each nostril. It is recommended to make the last application shortly before retiring to bed.

Paediatric population:

Otrivine Adult Nasal Drops should not be used in children aged less than 12 years old.

Route of administration: Nasal use.

1. Blow your nose gently.
2. Before using, practice using the dropper to develop good dosage control.
3. Tilt your head back as far as is comfortable or, if lying on a bed, hang the head over the side.
4. Without touching your nose with the dropper, apply the drops into each nostril and keep the head tilted back for a short time to allow the drops to spread throughout the nose.
5. If the drop completely misses your nose, administer the drop again.
6. If any part of the drop gets into your nose, do not administer the drop again.
7. Repeat with the other nostril.
8. Clean and dry the dropper before replacing it back into the bottle right after use.

4.3 Contraindications

Hypersensitivity to xylometazoline or to any of the excipients (see list in section 6.1).

Otrivine should not be used in patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Patients with acute coronary disease, hyperthyroidism or narrow angle glaucoma.

Use in patients who are receiving monoamine oxidase inhibitors, or within 14 days of stopping such treatments.

Rhinitis sicca and Atrophic rhinitis.

Otrivine 0.1% is contraindicated in children aged less than 12 years old.

4.4 Special warnings and precautions for use

Special warning and precautions for use

Otrivine, like other sympathomimetic agents, should be used only with caution in patients showing a strong reaction to adrenergic substances as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure.

Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias.

Like other topical vasoconstrictors, Otrivine should not be used for more than seven consecutive days: prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa.

Do not exceed the recommended dose, especially in children and in the elderly.

Otrivine should be used with caution in patients with

- hypertension, cardiovascular disease, diabetes mellitus, phaeochromocytoma, prostatic hypertrophy, and
- tri and tetra-cyclic antidepressant treatment (see section 4.5).

Keep out of the sight and reach of children.

For prevention of cross infection, it is recommended that each product package is used by one person only.

Paediatric population

The adult spray should not be used for infants or children under 12 years.

Information concerning excipients

Otrivine Adult Nasal Drops contains benzalkonium chloride which may cause irritation or swelling inside the nose, especially if used for a long time.

4.5 Interaction with other medicinal products and other forms of interaction

This product may alter the effects of some anti-hypertensives, such as beta-blockers, and of some anti-depressants, such as monoamine oxidase inhibitors (MAOIs), tricyclic and tetracyclic anti-depressants.

The concomitant use of xylometazoline with monoamine oxidase inhibitors (MAO) or tri- and tetra-cyclic antidepressants, may cause an increase in blood pressure due to the cardiovascular effects of these substances.

Monoamine oxidase inhibitors (MAO inhibitors): xylometazoline may potentiate the action of monoamine oxidase inhibitors and may induce hypertensive crisis. Xylometazoline is not recommended in patients who are taking or have taken MAOIs within the past two weeks (see section 4.3).

Tri- and tetra-cyclic antidepressants: concomitant use of tri- or tetra cyclic antidepressants and sympathomimetic preparations may result in an increased sympathomimetic effect of xylometazoline and is therefore not recommended.

4.6 Fertility, pregnancy and lactation

Pregnancy:

No foetal toxicity or fertility studies have been carried out in animals. In view of its potential systemic vasoconstrictor effect, Otrivine Adult Nasal Drops should not be used during pregnancy.

Breastfeeding:

There is no evidence of any adverse effect on the breast-fed infant. However, it is not known if xylometazoline is excreted in breast milk, therefore caution should be exercised and Otrivine Adult Nasal Drops should be used only under medical advice, whilst breast-feeding.

Fertility:

There are no adequate data for the effects of Otrivine Adult Nasal Drops on fertility and no animal studies are available. As the systemic exposure to xylometazoline hydrochloride is very low, effects on fertility are therefore very unlikely.

4.7 Effects on ability to drive and use machines

Otrivine has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The adverse effects listed below are classified by system organ class and frequency according to the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) or very rare ($< 1/10,000$).

MeDRA SOC	Adverse reaction	Frequency
Immune System Disorders	Hypersensitivity reaction (angioedema, rash, pruritus)	Very rare
Nervous System Disorders	Headache	Common
Eye Disorders	Transient visual impairment	Very rare
Cardiac Disorders	Heart rate irregular Heart rate increased	Very rare Very rare
Respiratory, thoracic and mediastinal disorders	Nasal Dryness Nasal Discomfort Epistaxis	Common Common Uncommon
Gastrointestinal disorders	Nausea	Common
General disorders and administration site	Application site burning	Common

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRC Pharmacovigilance, website: www.hpra.ie.

4.9 Overdose

Overdose of oral or excessive administration of topical xylometazoline hydrochloride may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This may include observation of the individual for at least several hours.

5 PHARMACOLOGICAL PROPERTIES**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: decongestants for topical use, sympathomimetics, plain. ATC Code: R01A A07.

Mechanism of action and pharmacodynamic effects:

Otrivine Adult Nasal Drops is a sympathomimetic agent with marked alpha-adrenergic activity, and is intended for use in the nose. It constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. It also reduces associated symptoms of mucus hypersecretion and facilitates drainage of blocked secretions. This enables patients suffering from colds to breathe more easily through the nose.

The effect of Otrivine begins within a few minutes and lasts for up to 10 hours. The effect of Otrivine Adult Nasal Drops is generally well tolerated and does not impair the function of ciliated epithelium.

5.2 Pharmacokinetic properties

Plasma concentrations of xylometazoline in man after local nasal application of the product are very low and close to the limit of detection.

Systemic absorption may occur following nasal application of xylometazoline hydrochloride solutions. It is not used systemically.

5.3 Preclinical safety data

Xylometazoline has no mutagenic effect. No teratogenic effects were known in a study where xylometazoline was given simultaneously in mice and rats.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride
Disodium phosphate dodecahydrate (Sodium phosphate)
Disodium edetate
Sodium dihydrogen phosphate dihydrate (Sodium acid phosphate)
Sodium chloride
Sorbitol liquid (Non-crystallising), E420
Hypromellose
Purified water

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Unopened: 3 years.

Opened: 28 days.

6.4 Special precautions for storage

Do not store above 25°C. Keep the bottle in the outer carton.

6.5 Nature and contents of container

Bottle	High density polyethylene
Cap	Polypropylene
Pipette rod	Low density polyethylene
Pipette bulb	Halogenated butyl elastomer
Carton	Cardboard

The pipette forms an integral part of the cap.

Pack size: 10 ml.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Haleon Ireland Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

8 MARKETING AUTHORISATION NUMBER

PA0678/120/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24 May 1984

Date of last renewal: 24 May 2009

10 DATE OF REVISION OF THE TEXT

November 2023